Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2065711 | 1.00 | MAPT (0.47) | MAPTALDH1A1POLBTDP1HTT | |
| SCHEMBL17297243 | 0.80 | ALDH1A1 (0.48) | MAPTALDH1A1POLBTDP1HDAC4 | |
| SCHEMBL9925191 | 0.79 | MAPT (0.51) | MAPTALDH1A1POLBTDP1HDAC4 | |
| SCHEMBL11025717 | 0.77 | ALDH1A1 (0.52) | MAPTALDH1A1POLBHTTAGTR1 | |
| SCHEMBL11025683 | 0.77 | ALDH1A1 (0.52) | MAPTALDH1A1POLBHTTAGTR1 | |
| SCHEMBL16211072 | 0.76 | ALDH1A1 (0.43) | MAPTALDH1A1POLBHTTGAA | |
| SCHEMBL12127344 | 0.73 | AGTR1 (0.53) | MAPTALDH1A1POLBTDP1HTT | |
| SCHEMBL11027185 | 0.73 | ALDH1A1 (0.58) | MAPTALDH1A1POLBTDP1HTT | |
| SCHEMBL11027188 | 0.73 | ALDH1A1 (0.58) | MAPTALDH1A1POLBTDP1HTT | |
| SCHEMBL2067138 | 0.73 | MAPT (0.53) | MAPTALDH1A1POLBTDP1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9199920-B2 | Antiviral drugs for treatment of arenavirus infection | Kineta Four, LLC (US) | 2015-12-01 | — | — | US | disclosed |
| US-9199920-B2 | Antiviral drugs for treatment of arenavirus infection | Kineta Four, LLC (US) | 2015-12-01 | — | — | US | disclosed |
| US-8492434-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492434-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-20130165493-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | Siga Technologies, Inc, (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165493-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | Siga Technologies, Inc, (US) | 2013-06-27 | — | — | US | disclosed |
| US-20120149751-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | SIGA TECHNOLOGIES, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149751-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | SIGA TECHNOLOGIES, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8148428-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148428-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090036513-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | SIGA TECHNOLOGIES, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| US-20090036513-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | SIGA TECHNOLOGIES, INC. (US) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165493-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | GK, ZC3HAV1, GALK1 | MAPT 814/4885ALDH1A1 4066/4885POLB 860/4885 |
| US-20090036513-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | GK, ZC3HAV1, GALK1 | MAPT 814/4885ALDH1A1 4066/4885POLB 860/4885 |
| US-20120149751-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | GK, ZC3HAV1, GALK1 | MAPT 814/4885ALDH1A1 4066/4885POLB 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.